Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease

Established in 1927 by the American College of Physicians

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease

View this table:
[in this window]
[in a new window]

Table 1. Baseline Characteristics of Patients*

View larger version (16K):
[in this window]
[in a new window]

Figure 1. Mean low-density lipoprotein (LDL) cholesterol levels (top) and mean triglyceride levels (bottom) among patients 65 years of age or older.

To convert LDL cholesterol values to mg/dL, divide by 0.02586. To convert triglyceride values to mg/dL, divide by 0.01129.

View this table:
[in this window]
[in a new window]

Table 2. Estimated Hazard Ratios for Individual Components of the Primary Outcome among Patients 65 Years of Age or Older*

View larger version (18K):
[in this window]
[in a new window]

Figure 2. Cumulative incidence of a major cardiovascular event (top) and fatal or nonfatal stroke (bottom).

The hazard ratio for a major cardiovascular event is 0.81 (95% CI, 0.67 to 0.98) (P = 0.03) among patients 65 years of age or older and 0.76 (CI, 0.64 to 0.90) (P = 0.001) among patients younger than 65 years of age. The hazard ratio for fatal or nonfatal stroke is 0.79 (CI, 0.57 to 1.09) (P = 0.158) and 0.70 (CI, 0.49 to 1.00) (P = 0.048), respectively.

View larger version (15K):
[in this window]
[in a new window]

Figure 3. Hazard ratios and heterogeneity tests for primary and secondary outcomes among patients 65 years of age or older (solid circles) and those younger than 65 years of age (open circles).

CA = cardiac arrest; CHD = coronary heart disease; CHF = congestive heart failure; CV = cardiovascular; MI = myocardial infarction; PAD = peripheral artery disease; PR = procedure-related. *P value for heterogeneity (patients $≥$ 65 years vs. patients <65 years).

View this table:
[in this window]
[in a new window]

Table 3. Safety Overview*